DEEPER CORONARY 6-Month Data Presented for Reflow’s Spur Elute System

May 22, 2026—Reflow Medical announced 6-month results from the DEEPER CORONARY first-in-human (FIH) pilot study evaluating the company’s investigational Spur Elute sirolimus-eluting, retrievable, coronary stent system for the treatment of coronary in-stent restenosis (ISR). The device features radially expandable spikes and an integrated balloon coated with Reflow’s sirolimus formulation, noted the company.

Reflow Medical stated that DEEPER CORONARY Principal Investigator Scott Harding, MD, presented the data at EuroPCR 2026 in Paris, France. Dr. Harding is Director of the Cardiology Research Group at Wellington Hospital in Wellington, New Zealand.

According to the company, DEEPER CORONARY is designed to evaluate the short-term safety of Spur Elute as a primary treatment for coronary ISR. In 2024, the company announced the commencement of the trial.

As summarized in the Reflow press release, the 6-month follow-up data demonstrated 100% freedom from major adverse cardiac events and 100% freedom from all-cause mortality in nine treated patients. The investigators also reported improvement in Canadian Cardiovascular Society angina class in all treated patients, with a median improvement of three classes.

“The 6-month data from DEEPER CORONARY provide encouraging acute and midterm safety and efficacy results utilizing the investigational Spur Elute system,” commented Dr. Harding in the press release. “These early findings support the continued clinical evaluation of this retrievable, sirolimus-eluting stent approach in ISR and further potential for coronary artery disease treatment.”